Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis

Annals of the Rheumatic Diseases

Volumn 65, Issue 8, 2006, Pages 1055-1059

  Mazzuca, Steven A ^a   Brandt, K D ^a   Eyre, D R ^b   Katz, B P ^a   Askew, J ^b   Lane, K A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CREATININE; DOXYCYCLINE; PROTEIN CTX II; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; FEMALE; HUMAN; JOINT CAVITY; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; VISUAL ANALOG SCALE;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLLAGEN TYPE II; DISEASE PROGRESSION; DOXYCYCLINE; FEMALE; HUMANS; KNEE JOINT; LEAST-SQUARES ANALYSIS; MIDDLE AGED; OBESITY; OSTEOARTHRITIS, KNEE; PEPTIDE FRAGMENTS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS;

EID: 33746483913     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.041582     Document Type: Article

References (36)

1. Poole AR. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am 2003;29:803-18.
2. Billinghurst RC, Dahlbert L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
3. Dahlbert L, Billinghurst C, Manner P, Ionescu M, Reiner A, Tanzer M, et al. Collagenase-mediated cleavage of type II collagen is selectively enhanced in osteoarthritis cartilage and can be arrested with a synthetic inhibitor which spares collagenase-1 (MMP-1). Arthritis Rheum 2000;43:673-82.
4. Squires G, Ionescu M, Okouneff S, Poole AR. The pathobiology of focal lesions development in aging human articular cartilage and molecular matrix changes characteristic of osteoarthritis. Arthritis Rheum 2003;48:1261-70.
5. Poole AR. Cartilage in health and disease. In:Koopman W, editor. Arthritis and allied conditions. A textbook of rheumatology, 14th edition. Philadelphia: Lippincott, Williams & Wilkins, 2001:226-84.
6. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
7. Eyre DR. Biochemical basis of collagen metabolites as bone turnover markers. In:Raisz L, Rodin G, Bilezikian JP, editors. Principles of bone biology. London: Academic Press, 1996:143-53.
8. Eyre DR, Shao P, Vosberg-Smith K, Weis M, Shaffer K, Yoshihara P. Cross-linked telopeptides from collagenase types I, II and III in human urine. J Bone Miner Res 1996;11(suppl):S193.
9. Norlund LL, Shao P, Yoshihara P, Eyre DR. Markers of bone type I and cartilage type II collagen degradation in the Hartley guinea pig model of osteoarthritis. Trans Orthop Res Soc (San Francisco) 1997;22:313.
10. Moskowitz RW, Holderbaum D, Atley LM, Eyre DR. Type II collagen C-telopeptide 2B4 epitope is a marker for cartilage degradation in familial osteoarthritis (abstract). Arthritis Rheum 1998;41:S352.
11. Atley LM, Sharma L, Clemens JD, Shaffer K, Pietka TA, Riggins JA, Eyre DR. The collagen II CTx degradation marker is generated by collagenase 3 and in urine reflects disease burden in knee OA patients (abstract). Trans Orthop Res Soc 2000;25:168.
12. Christgau S, Garnero P, Fledelius C, Moniz C, Ensign M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-15.
13. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001;60:619-26.
14. Lohmander LS, Atley LM, Pietka TA, Eyre DR. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003;48:3030-9.
15. Matyas JR, Atley L, Ionescu M, Eyre DR, Poole AR. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. Arthritis Rheum 2004;50:543-52.
16. Lindhorst E, Wachsmuth L, Kimmig N, Raiss R, Aigner T, Atley L, Eyre D. Increase in synovial fluid collagen type II degradation products after meniscectomy. Osteoarthritis Cartilage 2005;13:139-45.
17. Mazzuca SA, Brandt KD, Dieppe PA, Doherty M, Katz BP, Lane KA. Effect of alignment of the medial tibial plateau and x-ray beam on apparent progression of osteoarthritis in the standing anteroposterior knee radiograph. Arthritis Rheum 2001;44:1786-94.
18. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, et al. Effect of doxycycline on progression of osteoarthritis. Arthritis Rheum 2003;52:2015-25.
19. Kellgren JH, Lawrence JS. Radiographic assessment of osteoarthritis. Ann Rheum Dis 1957;16:494-502.
20. Najjar MF, Rowland M. Anthropometric reference data and prevalence of overweight-United States, 1976-80. Hyattsville, Maryland: National Center for Health Statistics, 1987; Department of Health and Human Services publication No (PHS) 87-1688 (Vital and Health Statistics, Series 11, No 238).
21. Mazzuca SA, Brandt KD, Buckwalter KA, Lequesne M. Pitfalls in the accurate measurement of joint space narrowing in semiflexed anteroposterior radiographs of the knee. Arthritis Rheum 2004;50:2508-15.
22. Buckland-Wright JC, Macfarlane DG, Williams SA, Ward RJ. Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees. Ann Rheum Dis 1995;54:872-80.
23. Strand V, Kelman A. Outcome measures in osteoarthritis: randomized controlled trials. Curr Rheum Rep 2004;6:20-30.
24. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimally clinically important improvement. Ann Rheum Dis 2005;64:29-33.
25. Eyre DR, Atley LM, Shao P, Vosberg-Smith K, Shaffer K, Ochs V, et al. Biochemical markers of bone and cartilage collagen degradation. In: Goldberg M, Boskey A, Robinson C, eds. Chemistry and biology of mineralized tissues. Rosemont, IL: American Academy of Orthopaedic Surgeons, 2000:347-50.
26. Atley LM, Shao P, Ochs V, Shaffer K, Eyre DR. Matrix metalloproteinase- mediated release of immunoreactive telopeptides from cartilage type II collagen (abstract). Trans Orthop Res Soc 1998;23:850.
27. Brandt KD. A pessimistic view of serologic markers for diagnosis and management of osteoarthritis. Biochemical, immunologic and clinicopathologic barriers. J Rheum 1989;16(suppl 18):39-42.
28. Gamero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001;60:619-26.
29. Reijman M, Hazes JMW, Bierma-Zeinstra SMA, Koes BW, Christgau S, Christiansen C, et al. A new marker for osteoarthritis. Cross-sectional and longitudinal approach. Arthritis Rheum 2004;50:2471-8.
30. Smith SM, Dillon EL, DeKerlegand DE, Davis-Street JE. Variability of collagen crosslinks: Impact of sample collection period. Calcif Tissue Int 2004;74:336-41.
31. Maziéres B, Garnero P, Gueguen A, Abbal M, Berdah L, Freiburghaus C, et al. Molecular markers of cartilage breakdown and synovitis are strong independent predictors of structural progression of hip osteoarthritis (abstract). The ECHODIAH cohort. Arthritis Rheum 2003;48(9 suppl):S683.
32. Garnero P, Ayral X, Rousseau J-C, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen synthesis and degradation predicts progression or joint damage in patients with knee osteoarthritis. Arthritis Rneum 2002;46:2613-24.
33. Garnero P, Bingham C, Aronstein W, Cohen S, Conaghan P, Cline G, et al. Treatment with risedronate reduced urinary CTX-II, a specific biochemical marker of cartilage type II collagen degradation, in a 24-month study of knee OA (abstract). Arthritis Rheum 2004;50(suppl 9):S656.
34. Bingham C, Aronstein W, Adami S, Cohen S, Conaghan P, Dougados M, et al. Treatment with risedronate reduced urinary CTX-II, a specific biochemical marker of cartilage type II collagen degradation, in a 24-month study of knee OA (abstract). Osteoarthritis Cartilage 2004;12(suppl B):S9.
35. Mouritzen U, Christgau S, Lehmann H-J, Tankó LB, Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003;62:332-6.
36. Mazzuca SA, Brandt KD, German C, Buckwalter KA, Lane KA, Katz BP. Development of radiographic changes of osteoarthritis in the "Chingford knee" reflects progression of disease or non-standardised positioning of the joint, rather than incident disease. Ann Rheum Dis 2003;62:1061-5.